Press releases

25
Jul 2024
20:30 E.S.T.

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Read more
28
Jun 2024
15:04 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Read more
20
Jun 2024
20:30 E.S.T.

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Read more
12
Jun 2024
14:27 E.S.T.

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Read more
4
Jun 2024
15:30 E.S.T.

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Read more
29
May 2024
20:30 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Read more
28
May 2024
20:30 E.S.T.

Cellectis Reports Financial Results for First Quarter 2024

Read more
25
May 2024
02:30 E.S.T.

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Read more
6
May 2024
06:05 E.S.T.

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

Read more
2
May 2024
18:49 E.S.T.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US